Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.

摘要: Abstract Background Findings of studies on the association between androgens and prostate cancer (PCa) are mixed. Androgens may affect prostate-specific antigen (PSA) levels, thereby influencing biopsy recommendations. Also, stimulate growth at very low levels with no additional effects higher (saturation model). Objective To test whether were associated PCa risk in placebo arm a prospective study which biopsies performed regardless PSA level. Design, setting, participants Of 8122 men Reduction by Dutasteride Prostate Cancer Events (REDUCE) trial, 4073 (50.1%) received placebo. Key entry criteria 2.5–10 ng/ml one prior negative biopsy. Intervention Per-protocol 2 4 yr; for-cause physician discretion. Outcome measurements statistical analysis Multivariable logistic regression was used to baseline log-transformed testosterone dihydrotestosterone (DHT) detecting either or low-grade (Gleason score 7). In secondary analysis, we stratified androgen (testosterone Results limitations men, 3255 (79.9%) had least after randomization analyzed. Androgen tested continuously quintiles generally unrelated detection grade. similar among compared normal (25.5% 25.1%; p =0.831). (odds ratio: 1.23; 95% confidence interval, 1.06–1.43; =0.006) only if ( =0.33). No found for DHT (all >0.85). Conclusions Baseline serum Our findings lowest being further changes support saturation model but must be confirmed future using an priori defined hypothesis. ClinicalTrials.gov identifier NCT00056407.